|
Jul 1
|
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 1
|
Akebia Therapeutics Reports Positive Results from its Vadadustat Global Phase 3 Clinical Trials
|
|
Jun 29
|
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees
|
|
Jun 23
|
Exploring 3 High Growth Tech Stocks In The US Market
|
|
Jun 17
|
Averoa secures EC authorisation for oral CKD treatment
|
|
May 28
|
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
|
|
May 27
|
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025
|
|
Mar 16
|
US$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results
|
|
Mar 14
|
Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ...
|
|
Mar 14
|
Q4 2024 Akebia Therapeutics Inc Earnings Call
|
|
Mar 13
|
Sector Update: Health Care Stocks Slipping Late Afternoon
|
|
Mar 13
|
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 13
|
Akebia Therapeutics: Q4 Earnings Snapshot
|
|
Mar 13
|
Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update
|
|
Mar 11
|
Exploring High Growth Tech Stocks In The US Market
|
|
Jan 3
|
New Strong Sell Stocks for January 3rd
|
|
Oct 10
|
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025
|
|
Oct 9
|
Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...
|
|
Oct 7
|
Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis
|
|
Sep 5
|
Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis
|